TCR2 Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch TCRR and buy or sell other stocks, options, and ETFs commission-free!About TCRR
TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains.
CEOGarry E. Menzel, PhD, MBA
CEOGarry E. Menzel, PhD, MBA
Employees—
Employees—
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2015
Founded2015
Employees—
Employees—
TCRR Key Statistics
Market cap58.08M
Market cap58.08M
Price-Earnings ratio-0.35
Price-Earnings ratio-0.35
Dividend yield—
Dividend yield—
Average volume694.31K
Average volume694.31K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$3.88
52 Week high$3.88
52 Week low$0.821
52 Week low$0.821